NDAORAL-21TABLET
Lifecycle
Pre-Launch
Data completeness
0/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ORTHO-NOVUM 1/80 21 is an oral contraceptive tablet combining mestranol (estrogen) and norethindrone (progestin) in a 21-day formulation. It prevents ovulation and alters cervical mucus to prevent pregnancy. This product represents a legacy oral contraceptive from the early era of hormonal birth control.
Post-LOE
Pre-launch status and absence of linked job openings suggest minimal active commercial infrastructure or potential niche/legacy positioning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings and pre-launch status indicate minimal near-term career opportunity or team expansion. This product offers limited visibility and growth potential compared to contemporary launches or growth-stage franchises.
Brand ManagerProduct Manager
Worked on ORTHO-NOVUM 1/80 21 at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.